Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 19Breast Neoplasms 18Melanoma 2Carcinoma, Non-Small-Cell Lung 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × toripalimab × Breast × Clear all
NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡